


SYMANSIS™

**Product Data Sheet****Compound Name****CHIR-258****Structure****CAS Number**

[405169-16-6]

**Chemical Formula:**C<sub>21</sub>H<sub>21</sub>FN<sub>6</sub>O**Molecular Weight:**

392.44

**Background information**

Mode of Action

Tyrosine kinase inhibitor

Predominant Target(s)

FGFR, VEGFR, PDGFR, FLT3, and KIT

Published Activity

For the treatment of a variety of malignancies in, also specifically inhibited proliferation and survival of the FGFR1OP2-FGFR1-positive KG1 and KG1A cell lines

Development stage

Phase 1 clinical trial

**References**

1. *A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.* Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S, Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS. **Clin Cancer Res.** **14(7):2075-81, 2008**
2. *Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.* Chase A, Grand FH, Cross NC. **Blood.** **110(10): 3729-34, 2007.**